Role of CCND1 and C-MYC oncogenes in metastatic breast cancer patients treated by herceptin

por Trojanec, R, Koudelakova, V, Bouchalova, K, Radova, L, Ondryasova, H, Krejci, E, Megova, M, Cizkova, M, Mlcochova, S, Melichar, B, Hajduch, M
Publicado 2011

BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients

por Bouchalova, K, Cizkova, M, Trojanec, R, Koudelakova, V, Radova, L, Furstova, J, Melichar, B, Cwiertka, K, Kharaishvili, G, Kolar, Z, Hajduch, M
Publicado 2011